Expression of PSMD2 gene in hepatocellular carcinoma and its correlation with immune checkpoints and prognosis DOI Creative Commons

Gu MeiYing,

Wanlong Ma,

Zi-min Ma

и другие.

Scientific Reports, Год журнала: 2025, Номер 15(1)

Опубликована: Март 24, 2025

Hepatocellular carcinoma (HCC) is a prevalent and fatal tumor globally, characterized by complex pathogenesis poor prognosis. Despite significant advancements in the application of immune checkpoint inhibitors (ICIs) for cancer treatment, efficacy immunotherapy HCC remains suboptimal. PSMD2, crucial regulator ubiquitin-proteasome system, has attracted increasing attention its involvement various cancers; however, functions mechanisms are still poorly understood. This study aims to investigate expression PSMD2 HCC, association with prognosis, interaction checkpoints, thus establishing foundation further exploration role evasion HCC. We analyzed levels adjacent normal tissues utilizing GEPIA TIMER databases. Cox regression analysis was performed using R software evaluate relationship between Furthermore, we assessed correlation cell infiltration, as well including PD1, PD-L1, CTLA-4, tools. Additionally, examined therapy response through Tumor Immune Dysfunction Exclusion (TIDE) analysis. Finally, constructed protein-protein (PPI) network STRING database Cytoscape software, followed Gene Set Enrichment Analysis (GSEA). significantly overexpressed closely correlated prognosis (HR = 1.61, P 2.0e-4). infiltration demonstrated that positively several genes, types. TIDE indicated elevated associated increased potential immunotherapy. GSEA enrichment revealed primarily enriched p53 signaling pathway, ubiquitin-mediated proteolysis other cancer-related pathways. The not only but may also play modulating immunity, thereby affecting patient responses Consequently, presents promising novel therapeutic target biomarker

Язык: Английский

Expression of PSMD2 gene in hepatocellular carcinoma and its correlation with immune checkpoints and prognosis DOI Creative Commons

Gu MeiYing,

Wanlong Ma,

Zi-min Ma

и другие.

Scientific Reports, Год журнала: 2025, Номер 15(1)

Опубликована: Март 24, 2025

Hepatocellular carcinoma (HCC) is a prevalent and fatal tumor globally, characterized by complex pathogenesis poor prognosis. Despite significant advancements in the application of immune checkpoint inhibitors (ICIs) for cancer treatment, efficacy immunotherapy HCC remains suboptimal. PSMD2, crucial regulator ubiquitin-proteasome system, has attracted increasing attention its involvement various cancers; however, functions mechanisms are still poorly understood. This study aims to investigate expression PSMD2 HCC, association with prognosis, interaction checkpoints, thus establishing foundation further exploration role evasion HCC. We analyzed levels adjacent normal tissues utilizing GEPIA TIMER databases. Cox regression analysis was performed using R software evaluate relationship between Furthermore, we assessed correlation cell infiltration, as well including PD1, PD-L1, CTLA-4, tools. Additionally, examined therapy response through Tumor Immune Dysfunction Exclusion (TIDE) analysis. Finally, constructed protein-protein (PPI) network STRING database Cytoscape software, followed Gene Set Enrichment Analysis (GSEA). significantly overexpressed closely correlated prognosis (HR = 1.61, P 2.0e-4). infiltration demonstrated that positively several genes, types. TIDE indicated elevated associated increased potential immunotherapy. GSEA enrichment revealed primarily enriched p53 signaling pathway, ubiquitin-mediated proteolysis other cancer-related pathways. The not only but may also play modulating immunity, thereby affecting patient responses Consequently, presents promising novel therapeutic target biomarker

Язык: Английский

Процитировано

0